Infographic: USMCA and the May 10 Trade Amendments
AAM All Access Podcast - AAM CEO Dan Leonard convenes industry and policy experts to explore why the Inflation Reduction Act (f/k/a Build Back Better) reduces generic and biosimilar competition.

Anniversary of the May 10 Trade Amendments

Together We Can Fix the USMCA

In 2007, a divided government compromised and agreed to advance America’s trade priorities. With bipartisan consensus to lower prescription drug costs, will the current political dynamic allow a similar deal?

Now is the time to rally and deliver for patients in the U.S. who are already confronted by the world’s longest climb to affordable medicines. As currently constructed, NAFTA 2.0 (USMCA) will eliminate easier routes and keeps drug prices out of reach for American patients.

Twelve years ago, lawmakers prioritized patient access to affordable medicine. We can do it again and fix the USMCA. Let’s work together to fix the new trade agreement and lower drug prices for for America's patients.

AAM NAFTA 2.0 Fix USMCA

Download Infographic

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.